Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Medical Countermeasures

    Tekmira Starts Limited Manufacturing of Ebola Therapeutic

    By Global Biodefense StaffOctober 23, 2014
    Ebola Virus Research Sudan Strain
    Image courtesy of NIAID
    Share
    Facebook LinkedIn Reddit Email

    Tekmira Pharmaceuticals yesterday announced it has commenced limited GMP manufacture of TKM-Ebola, an RNAi therapeutic specifically targeting the Ebola – Guinea virus variant.

    Tekmira has completed the design of a modified RNAi therapeutic specifically targeting the Guinea viral variant, now termed Ebola-Guinea, which is the variant responsible for the Ebola epidemic currently prevalent in West Africa.

    Supply of this new product is expected to be available in early December 2014 for potential use by various collaborators.

    The FDA previously authorized the company to provide TKM-Ebola for treatment under expanded access protocols to patients with confirmed or suspected Ebola virus infections. The current supply of TKM-Ebola inventory is limited. However, Tekmira intends to continue to provide TKM-Ebola, if requested, to patients with confirmed or suspected Ebola virus infections under this regulatory framework.

    “To date, several patients have been treated with the product and data collected will be provided to the FDA under the Company’s Investigational New Drug Application (IND),” stated the Tekmira announcement.  “We have established a similar framework with Health Canada for the potential use of TKM-Ebola for patients with confirmed or suspected Ebola virus infections.”

    In September, Tekmira joined an international consortium facilitating expedited clinical trials in West Africa for Ebola Virus Disease countermeasures in West Africa.

    The Company’s IND for TKM-Ebola remains on partial clinical hold with respect to the multiple ascending dosing in healthy subjects, which the company expects to be resolved this quarter.

    TKM-Ebola is backed by a $140M contract with the U.S. Department of Defense Joint Project Manager Medical Countermeasure Systems (JPM-MCS). JPM-MCS, a component of the Joint Program Executive Office for Chemical and Biological Defense, aims to provide U.S. military forces and the nation with safe, effective, and innovative medical solutions to counter chemical, biological, radiological, and nuclear threats.

    Source: Tekmira press release, adapted.

    Ebola Emerging Threats
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleWhy Some Adults Were More Susceptible To Last Year’s Flu
    Next Article Winning the War Against Human Parainfluenza Virus

    Related Stories

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    The Basics on the Nipah Virus Outbreak in India

    September 19, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023

    Bird Flu Undergoing Changes That Could Increase Risk of Widespread Human Transmission

    September 14, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.